These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25677105)

  • 1. Development of virus-like particles for diagnostic and prophylactic biomedical applications.
    Schwarz B; Douglas T
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(5):722-35. PubMed ID: 25677105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology.
    Schwarz B; Uchida M; Douglas T
    Adv Virus Res; 2017; 97():1-60. PubMed ID: 28057256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Virus-Like Particles in Medical Biotechnology.
    Comas-Garcia M; Colunga-Saucedo M; Rosales-Mendoza S
    Mol Pharm; 2020 Dec; 17(12):4407-4420. PubMed ID: 33147978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.
    Schwarz B; Madden P; Avera J; Gordon B; Larson K; Miettinen HM; Uchida M; LaFrance B; Basu G; Rynda-Apple A; Douglas T
    ACS Nano; 2015 Sep; 9(9):9134-47. PubMed ID: 26266824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System.
    Mohsen MO; Gomes AC; Vogel M; Bachmann MF
    Vaccines (Basel); 2018 Jul; 6(3):. PubMed ID: 30004398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
    Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
    Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine.
    Shukla S; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(5):708-21. PubMed ID: 25683790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical stabilization of Norwalk virus-like particles.
    Kissmann J; Ausar SF; Foubert TR; Brock J; Switzer MH; Detzi EJ; Vedvick TS; Middaugh CR
    J Pharm Sci; 2008 Oct; 97(10):4208-18. PubMed ID: 18300304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Virus-like Particles for Antigen and Drug Delivery.
    Hill BD; Zak A; Khera E; Wen F
    Curr Protein Pept Sci; 2018; 19(1):112-127. PubMed ID: 27875963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of novel vaccines based on virus-like particles or chimeric virions.
    Bárcena J; Blanco E
    Subcell Biochem; 2013; 68():631-65. PubMed ID: 23737067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of viral nanoparticles in medicine.
    Yildiz I; Shukla S; Steinmetz NF
    Curr Opin Biotechnol; 2011 Dec; 22(6):901-8. PubMed ID: 21592772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient disulfide bond formation in virus-like particles.
    Bundy BC; Swartz JR
    J Biotechnol; 2011 Jul; 154(4):230-9. PubMed ID: 21536082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
    Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomolecular engineering of virus-like particles aided by computational chemistry methods.
    Zhang L; Lua LH; Middelberg AP; Sun Y; Connors NK
    Chem Soc Rev; 2015 Dec; 44(23):8608-18. PubMed ID: 26383145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures.
    Pushko P; Pumpens P; Grens E
    Intervirology; 2013; 56(3):141-65. PubMed ID: 23594863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing physicochemical properties of virus capsids for designing enzyme confined nanocompartments.
    Uchida M; Manzo E; Echeveria D; Jiménez S; Lovell L
    Curr Opin Virol; 2022 Feb; 52():250-257. PubMed ID: 34974380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88.
    Yang R; Murillo FM; Cui H; Blosser R; Uematsu S; Takeda K; Akira S; Viscidi RP; Roden RB
    J Virol; 2004 Oct; 78(20):11152-60. PubMed ID: 15452235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fundamental developments in infrared spectroscopic imaging for biomedical applications.
    Pilling M; Gardner P
    Chem Soc Rev; 2016 Apr; 45(7):1935-57. PubMed ID: 26996636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.